Serum total L-carnitine levels in non-obese women with polycystic ovary syndrome

Human Reproduction

Volumn 23, Issue 7, 2008, Pages 1602-1606

  Fenkci, Semin Melahat ^a,c   Fenkci, Veysel ^b   Oztekin, Ozer ^a   Rota, Simin ^a   Karagenc, Nedim ^a  

^a PAMUKKALE UNIVERSITY   (Turkey)

^b Clinics of Obstetrics and Gynaecology   (Turkey)

^c NONE   (Turkey)

Author keywords

Carnitine; Glucose metabolism; Hyperandrogenism; Insulin resistance; PCOS

Indexed keywords

ANDROGEN; CARNITINE; GLUCOSE; GONADOTROPIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LUTEINIZING HORMONE; PRASTERONE SULFATE; SEX HORMONE BINDING GLOBULIN; TESTOSTERONE;

ADOLESCENT; ADULT; ARTICLE; BODY MASS; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GLUCOSE METABOLISM; HUMAN; INSULIN RESISTANCE; OVARY POLYCYSTIC DISEASE; PROTEIN BLOOD LEVEL;

EID: 44949175928     PISSN: 02681161     EISSN: 14602350     Source Type: Journal    
DOI: 10.1093/humrep/den109     Document Type: Article

References (38)

1. Arockia Rani PJ, Panneerselvam C. Carnitine as a free radical scavenger in aging. Exp Gerontol 2001;36:1713-1726.
2. Arslanian SA, Lewy VD, Danadian K. Glucose intolerance in obese adolescents with polycystic ovary syndrome: roles of insulin resistance and beta-cell dysfunction and risk of cardiovascular disease. J Clin Endocrinol Metab 2001;86:66-71.
3. Asuncion M, Calvo RM, San Millan JL, Sancho J, Avila S, Escobar-Morreale HF. A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain. J Clin Endocrinol Metab 2000;85:2434-2438.
4. Betteridge DJ. What is the oxidative stress? Metabolism 2000;49:3-8.
5. Borum PR. Regulation of the carnitine concentration in plasma. In: Frenkel RA, McGarry JD (eds). Carnitine Biosynthesis, Metabolism and Functions. New York, USA: Academic Press, 1980,115-126.
6. Bremer J. Carnitine-metabolism and functions. Physiol Rev 1983;63:1420-1480.
7. Broderick TL, Quinney HA, Lopaschuk GD. Carnitine stimulation of glucose oxidation in the fatty acid perfused isolated working rat heart. J Biol Chem 1992;267:3758-3763.
8. Chiu KM, Schmidt MJ, Havighurst TC, Shug AL, Daynes RA, Keller ET, Gravenstein S. Correlation of serum L-carnitine and dehydroepiandrosterone sulphate levels with age and sex in healthy adults. Age Ageing 1999;28:211-216.
9. Cipolla MJ, Nicoloff A, Rebello T, Amato A, Porter JM. Propionyl- l-carnitine dilates human subcutaneous arteries through an endothelium-dependent mechanism. J Vasc Surg 1999;29:1097-1103.
10. DeFronzo RA, Ferrannini E. Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 1991;14:173-194.
11. De Gaetano A, Mingrone G, Castagneto M, Calvani M. Carnitine increases glucose disposal in humans. J Am Coll Nutr 1999;18:289-295.
12. Dunaif A, Segal KR, Futterweit W, Dobrjansky A. Profound peripheral insulin resistance independent of obesity in polycystic ovary syndrome. Diabetes 1989;38:1165-1174.
13. Dunaif A, Givens J, Haseltine F, Merriam G. Current issues in endocrinology and metabolism: polycystic ovary syndrome. Acute augmentation of plasma androstenedione and dehydroepiandrosterone by euglycemic insulin infusion: evidence for a direct effect of insulin on ovarian steroidogenesis. Cambridge, UK: Blackwell, 1992.
14. Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev 1997;18:774-800.
15. Fenkci V, Fenkci S, Yilmazer M, Serteser M. Decreased total antioxidant status and increased oxidative stress in women with polycystic ovary syndrome may contribute to the risk of cardiovascular disease. Fertil Steril 2003;80:123-127.
16. Ferrari R, Merli E, Cicchitelli G, Mele D, Fucili A, Ceconi C. Therapeutic effects of L-carnitine and propionyl-L-carnitine on cardiovascular diseases: a review. Ann N Y Acad Sci 2004;1033:79-91.
17. Ferriman D, Gallwey JD. Clinical assessment of body hair growth in women. J Clin Endocrinol Metab 1961;21:1440-1447.
18. Gómez-Amores L, Mate A, Revilla E, Santa-María C, Vázquez CM. Antioxidant activity of propionyl-L-carnitine in liver and heart of spontaneously hypertensive rats. Life Sci 2006;78:1945- 1952.
19. Irat AM, Aktan F, Ozansoy G. Effects of L-carnitine treatment on oxidant/antioxidant state and vascular reactivity of streptozotocin-diabetic rat aorta. J Pharm Pharmacol 2003;55:1389-1395.
20. Lango R, Smoleński RT, Rogowski J, Siebert J, Wujtewicz M, Słomińska EM, Łysiak-Szydłowska W, Yacoub MH. Propionyl-L-carnitine improves hemodynamics and metabolic markers of cardiac perfusion during coronary surgery in diabetic patients. Cardiovasc Drugs Ther 2005;19:267-275.
21. Lysiak W, Lilly K, DiLisa F, Toth PP, Bieber LL. Quantitation of the effect of L-carnitine on the levels of acid-soluble short-chain acyl-CoA and CoASH in rat heart and liver mitochondria. J Biol Chem 1988;263:1151-1156.
22. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and b-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-419.
23. Mauriello A, Sangiorgi G, Orlandi A, Schiaroli S, Perfumo S, Spagnoli LG. Effect of long-term treatment with propionyl-l carnitine on smooth muscle cell polyploidy in spontaneously hypertensive rats. Hypertension 1996;28:177-182.
24. Mingrone G, Greco AV, Capristo E, Benedetti G, Giancaterini A, De Gaetano A, Gasbarrini G. L-carnitine improves glucose disposal in type 2 diabetic patients. J Am Coll Nutr 1999;18:77-82.
25. Mingrone G. Carnitine in type 2 diabetes. Ann N Y Acad Sci 2004;1033:99-107.
26. Mister M, Noris M, Szymczuk J, Azzollini N, Aiello S, Abbate M, Trochimowicz L, Gagliardini E, Arduini A, Perico N et al. Propionyl-l-carnitine prevents renal function deterioration due to ischemia/reperfusion. Kidney Int 2002;61:1064-1078.
27. Opalka JR, Gellerich FN, Zierz S. Age and sex dependency of carnitine concentration in human serum and skeletal muscle. Clin Chem 2001;47:2150-2153.
28. Power RA, Hulver MW, Zhang JY, Dubois J, Marchand RM, Ilkayeva O, Muoio DM, Mynatt RL. Carnitine revisited: potential use as adjunctive treatment in diabetes. Diabetologia 2007;50:824-832.
29. Reda E, D'Iddio S, Nicolai R, Benatti P, Calvani M. The carnitine system and body composition. Acta Diabetol 2003;40:106-113.
30. Savitha S, Panneerselvam C. Mitochondrial membrane damage during aging process in rat heart: potential efficacy of L-carnitine and DL alpha lipoic acid. Mech Ageing Dev 2006;127:349-355.
31. Sealey JE, Laragh JH. RIA of plasma renin activity. Semin Nucl Med 1975;5:189-202.
32. Sealey JE. Plasma renin activity and plasma prorenin assays. Clin Chem 1991;37:1811-1819.
33. Sethi R, Dhalla KS, Ganguly PK, Ferrari R, Dhalla NS. Beneficial effects of propionyl L-carnitine on sarcolemmal changes in congestive heart failure due to myocardial infarction. Cardiovasc Res 1999;42:607-615.
34. Stephens FB, Constantin-Teodosiu D, Laithwaite D, Simpson EJ, Greenhaff PL. A threshold exists for the stimulatory effect of insulin on plasma L-carnitine clearance in humans. Am J Physiol Endocrinol Metab 2007;292:637-641.
35. The Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004;81:19-25.
36. Takiyama N, Matsumoto K. Age-and sex-related differences of serum carnitine in a Japanese population. J Am Coll Nutr 1998;17:71-74.
37. Vanella A, Russo A, Acquaviva R, Campisi A, Di Giacomo C, Sorrenti V, Barcellona ML. l-propionyl-carnitine as uperoxide scavenger, antioxidant, and DNA cleavage protector. Cell Biol Toxicol 2000;16:99-104.
38. Vescovo G, Ravara B, Gobbo V, Sandri M, Angelini A, Della Barbera M, Dona M, Peluso G, Calvani M, Mosconi L et al. L-Carnitine: a potential treatment for blocking apoptosis and preventing skeletal muscle myopathy in heart failure. Am J Physiol Cell Physiol 2002;283:802-810.